A Phase II Clinical Study for Evaluating the Efficacy and Safety of Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone in Transplantation-Eligible Elderly Patients with Newly Diagnosed Multiple Myeloma (KMM2101)

被引：0
|
作者：
Yoon, Sang Eun [1 ]
Jung, Sung-Hoon [2 ]
Lee, Gyeong Won [3 ]
Min, Chang-Ki [4 ]
Byun, Ja Min [5 ]
Kwak, Jae-Yong [6 ]
Lee, Myung-Won [7 ]
Lee, Ho Sup [8 ]
Kim, Seok Jin [9 ]
Kim, Kihyun [1 ,10 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Div Hematol Oncol, Samsung Med Ctr,Dept Med, Seoul, South Korea
[2] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Hwasun, South Korea
[3] Gyeongsang Natl Univ, Coll Med, Gyeongsang Natl Univ Hosp, Dept Internal Med, Jinju, South Korea
[4] Catholic Univ Korea, Catholic Hematol Hosp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea
[5] Seoul Natl Univ, Seoul, South Korea
[6] Chonbuk Natl Univ, Med Sch, Jeonju, South Korea
[7] Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea
[8] Kosin Univ Gospel Hosp, Dept Internal Med, Busan, South Korea
[9] Samsung Med Ctr, Seoul, South Korea
[10] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198947
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7045 / 7046
页数：2
相关论文
共 50 条
  • [41] Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
    Enrique M. Ocio
    Aurore Perrot
    Pierre Bories
    Jesus F. San-Miguel
    Igor W. Blau
    Lionel Karlin
    Joaquin Martinez-Lopez
    Song-Yau Wang
    Sara Bringhen
    Magda Marcatti
    María-Victoria Mateos
    Paula Rodriguez-Otero
    Stefania Oliva
    Axel Nogai
    Nadia Le Roux
    Liyan Dong
    Sandrine Macé
    Matthieu Gassiot
    Thomas Fitzmaurice
    Corina Oprea
    Philippe Moreau
    Leukemia, 2023, 37 : 1521 - 1529
  • [42] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
    White, Darrell J.
    Lentzsch, Suzanne
    Gasparetto, Cristina
    Bahlis, Nizar
    Chen, Christine I.
    Lipe, Brea C.
    Schiller, Gary J.
    Tuchman, Sascha A.
    Sutherland, Heather J.
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Callander, Natalie Scott
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Baljevic, Muhamed
    BLOOD, 2019, 134
  • [43] SAFETY AND EFFICACY OF LENALIDOMIDE PLUS DEXAMETHASONE IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS 70 YEARS OF AGE AND OLDER
    Gay, F.
    Hayman, S.
    Buadi, F.
    Detweiler-Short, K.
    Lacy, M.
    Kumar, S.
    Dispenzieri, A.
    Gertz, M.
    Rajkumar, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 153 - 153
  • [44] A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41)
    O'Donnell, Elizabeth K.
    Suman, Vera Jean
    Geyer, Susan M.
    Nadeem, Omar
    Dinner, Shira
    Yee, Andrew J.
    Laubach, Jacob P.
    Mo, Clifton C.
    Tuchman, Sascha A.
    Donadio, Kristen
    Sinclair, Sarah
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [45] A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
    O'Donnell, Elizabeth K.
    Mo, Clifton C.
    Yee, Andrew J.
    Nadeem, Omar
    Branagan, Andrew R.
    Laubach, Jacob P.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette
    Harrington, Cynthia C.
    Agyemang, Emerentia
    Spillane, Kerry
    LaStofka, Brenton
    Rosenblatt, Jacalyn
    Raje, Noopur S.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [46] A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
    Ocio, Enrique M.
    Bringhen, Sara
    Oliva, Stefania
    Rodriguez-Otero, Paula
    Kanagavel, Dheepak
    Oprea, Corina
    Wei, Vivian
    Doroumian, Severine
    Martinez-Lopez, Joaquin
    BLOOD, 2017, 130
  • [47] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Kapoor, Prashant
    Gertz, Morie A.
    Laplant, Betsy
    Malave, Gabriella C.
    Wolfe, Eric
    Muchtar, Eli
    Siddiqui, Mustaqeem A.
    Gonsalves, Wilson I.
    Emanuel, Angie R.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Buadi, Francis K.
    Hayman, Suzanne R.
    Leung, Nelson
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Dispenzieri, Angela
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134
  • [48] MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Bhutani, Manisha
    Robinson, Myra
    Foureau, David
    Atrash, Shebli
    Paul, Barry
    Guo, Fei
    Grayson, Jason M.
    Ivanina-Foureau, Anna
    Pineda-Roman, Mauricio
    Varga, Cindy
    Friend, Reed
    Ferreri, Christopher J.
    Begic, Xhevahire
    Norek, Sarah
    Drennan, Tiffany
    Anderson, Michelle B.
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad Z.
    BLOOD ADVANCES, 2025, 9 (03) : 507 - 519
  • [49] Phase II Clinical Trial of Lenalidomide and Dexamethasone Therapy in Japanese Elderly Patients With Newly Diagnosed Multiple Myeloma to Determine Optimal Plasma Concentration of Lenalidomide
    Kobayashi, Takahiro
    Miura, Masatomo
    Niioka, Takenori
    Abumiya, Maiko
    Ito, Fumiko
    Kobayashi, Isuzu
    Ikeda, Sho
    Yoshioka, Tomoko
    Kameoka, Yoshihiro
    Takahashi, Naoto
    THERAPEUTIC DRUG MONITORING, 2018, 40 (03) : 301 - 309
  • [50] Efficacy of Induction Thearapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients
    Joseph, Nisha
    Gupta, Vikas A.
    Hofmeister, Craig C.
    Gleason, Charise
    Heffner, Leonard
    Boise, Lawrence H.
    Kaufman, Jonathan L.
    Dhodapkar, Madhav V.
    Lonial, Sagar
    Nooka, Ajay K.
    BLOOD, 2018, 132
12345